On March 6, 2025, Trestle Biotherapeutics, Inc. announced a research collaboration with Humacyte, Inc. The partnership aims to explore technology synergies for bioengineering vascularized organs for transplantation.
The collaboration, formalized through a material transfer agreement, will investigate the interaction of Trestle Bio’s biofabricated human kidney tissues with Humacyte’s acellular tissue engineered vessel (ATEV™). The goal is to generate a human bioengineered kidney with vascular perfusion.
This initiative offers both companies an opportunity to expand their R&D programs, with Humacyte leveraging its FDA-approved regenerative medicine product expertise. The collaboration targets end-stage renal disease (ESRD), a condition affecting over 800 million patients globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.